Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet(Universitätsklinikum Krems), Noopur Raje(Massachusetts General Hospital), Samantha Pozzi(University of Modena and Reggio Emilia), Kishan Patel(Harvard University), Kenneth C. Anderson(Massachusetts Eye and Ear Infirmary), Nikhil C. Munshi(Dana-Farber Cancer Institute), Jasbir Seehra, Michael Churchill(Harvard University), Mariateresa Fulciniti(Dana-Farber Cancer Institute), Wanling Xie(Dana-Farber Cancer Institute), Ralph Weissleder(Harvard University), Siddhartha Mukherjee(NewYork–Presbyterian Hospital), David T. Scadden(Harvard University), Diana Cirstea(Dana-Farber Cancer Institute), Aliyah R. Sohani(Massachusetts General Hospital), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Teru Hideshima(Harvard University), Loredana Santo(Azienda Ospedaliero Universitaria San Giovanni Battista), Jesse Schoonmaker(Harvard University), A.R. Guimarães(Harvard University), Edie Weller(Boston Children's Hospital), Nileshwari Vaghela(Harvard University), Dharminder Chauhan(Cancer Clinic)
Cited by 235
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Imaging in the era of molecular oncology
|Nature|2008|2.3k